Poseida Therapeutics, Inc. - Common Stock (PSTX)

Roche agrees to acquire Poseida Therapeutics for $1.5 billion, expanding its CAR-T therapy platform with a focus on hematologic malignancies and solid tumors.

PSTX stock results show that Poseida Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

PSTX stock results show that Poseida Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

Pre-market stock movers are worth diving into on Tuesday as we check out all of the biggest changes and the news behind them!

Shares of Mesoblast Limited (NASDAQ: MESO) rose sharply during Monday’s session after the company announced FDA support of an accelerated approval pathway for rexlemestrocel-L in end-stage heart failure patients. Mesoblast shares jumped 13.4% to $2.4399 on Monday.

U.S. stocks were lower, with the Dow Jones index falling more than 150 points on Monday.

PSTX stock results show that Poseida Therapeutics beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023.

Poseida Therapeutics Inc (NASDAQ: PSTX) released early efficacy and safety results from its Phase 1 study of P-BCMA-ALLO1, its BCMA-targeted allogeneic, T stem cell memory (TSCM)-rich chimeric antigen receptor 

It's time to start the trading week with a look at the biggest pre-market stock movers worth watching for Monday morning!

Are you looking for biotech breakthrough stocks? Here are three revolutionary stocks redefining healthcare.

Are you looking to invest in biotechnology breakthroughs? Here are three biotech stocks that could make early investors rich.